For research use only. Not for therapeutic Use.
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
Pembrolizumab (MK-3475) increases the secretion of cytokines IFN-γ, TNF-α and the apoptotic cell death of A549 cells[2].
Pembrolizumab improves the αROR1-CAR T-mediated cytotoxicity, and reduces tumorigenesis in the co-cultured αROR1-CAR T and A549 cells by blocking PD-1::PD-L1 interaction in αROR1-CAR T cells[2].
Pembrolizumab inhibits tumor size in A549 xenograft mice pretreated by pressure[2].
Catalog Number | A001235 |
CAS Number | 1374853-91-4 |
Purity | ≥95% |
Reference | [1]. Amita Patnaik, et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res.2015Oct1;21(19):4286-93. [2]. Zhenglin Ou, et al. Pressure increases PD‑L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti‑ROR1 CAR T cell‑mediated cytotoxicity, Sci Rep [3]. Amita Patnaik, et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res.2015Oct1;21(19):4286-93. [4]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X. |